2 Biotech Takeout Targets Perfect for Biogen

2 Biotech Takeout Targets Perfect for Biogen

Source: 
Motley Fool
snippet: 

Biogen (NASDAQ: BIIB) recently suffered a brutal stock market beating after its big Alzheimer's candidate failed to make a difference for patients with early signs of the disease.

Biogen's market value was reduced by nearly a third in a few short days, and that puts it in range for a big pharma buyout. If Biogen follows the standard industry handbook, management will acquire a medium-sized biotech soon.